Matrix metalloproteinase 2 (MMP-2) and its tissue inhibitor 2 (TIMP-2) in pancreatic cancer (PC)
Metrics: PDF 121 views | HTML 188 views | ?
Marta Łukaszewicz-Zając1, Mariusz Gryko2, Sara Pączek1, Maciej Szmitkowski1, Bogusław Kędra2 and Barbara Mroczko1,3
1Department of Biochemical Diagnostics, Medical University of Białystok, Białystok, Poland
2Second Department of General Surgery, Medical University of Bialystok, Bialystok, Poland
3Department of Neurodegeneration Diagnostics, Medical University of Białystok, Białystok, Poland
Barbara Mroczko, email: email@example.com
Keywords: biomarker; matrix metalloproteinases; pancreatic cancer
Received: November 13, 2018 Accepted: December 27, 2018 Published: January 08, 2019
Objectives: The incidence rate of pancreatic cancer (PC) is similar to mortality rate, thus searching specific tumor biomarkers of PC is sorely needed. Matrix metalloproteinase-2 (MMP-2) and the imbalance between MMP-2 and its tissue inhibitor (TIMP-2) play a critical role in tumor progression. We aim to assess the diagnostic and prognostic usefulness of serum MMP-2 and TIMP-2 as potential biomarkers in comparison to well-established tumor markers of PC (CA 19-9, carbohydrate antigen 19-9 and CEA, carcinoembryonic antigen).
Results: We indicated the significant differences between serum TIMP-2 concentrations in PC patients, CP individuals and control group. The diagnostic sensitivity of TIMP-2 was the highest among all proteins tested and increased up to 96% in combined measurement with MMP-2. The area under ROC curve (AUC) for TIMP-2 was larger than for MMP-2, but lower than for classical tumor markers.
Methods: Presented study comprised on 226 subjects, including 92 PC patients, 43 chronic pancreatitis (CP) patients and 91 healthy volunteers. The serum concentrations of these proteins were measured using immunological methods.
Conclusions: Presented findings suggest higher usefulness of TIMP-2 than MMP-2 as potential biomarker in the diagnosis of PC patients, however more studies on large population are needed to support our results.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.